Clover Health Investments, Corp. — Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports a corporate governance event. The earliest reported event occurred on November 28, 2022; the filing was signed November 30, 2022. Clover Health Investments, Corp. is a Delaware company whose Class A common stock trades on Nasdaq under the symbol CLOV.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating and financial metrics.
Material Changes
- On November 28, 2022, the Board appointed Anna Loengard, M.D., as a Class I director.
- Dr. Loengard had not been appointed to any Board committee as of the filing date.
- She will receive a prorated portion of the 2022 annual Board retainer.
- She will receive a restricted stock unit award with a stated annual value of $200,000, prorated for her service from appointment through December 31, 2022.
- Dr. Loengard entered into the Company’s standard director indemnification agreement, including indemnification and advancement of expenses.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance or operating outlook. It states that there were no arrangements or understandings with other persons regarding Dr. Loengard’s selection, no family relationships with Clover directors or executive officers, and no reportable material related-party transaction under Item 404(a) of Regulation S-K.
The primary potential financial impact disclosed is director compensation, including the prorated cash retainer and prorated RSU award. The filing does not state the number of RSUs to be issued or their vesting terms.
Investor Verification Items
- Verify the final terms, share count, and vesting conditions of Dr. Loengard’s prorated RSU award.
- Review subsequent filings for any committee appointment or changes to Board composition.
- Review the referenced November 30, 2022 press release, filed as Exhibit 99.1, for additional information about the appointment.
- Confirm the distinction between the November 28 earliest event date and the November 30 filing and press-release date.